Kymera Investor Presentation Deck

● Phase 1 results in healthy volunteers and patients support Phase 2 advancement Sanofi responsible for program development costs Kymera retains option (before Phase 3) for cost and profit sharing First development milestones achieved in Q4 2023 $55 million combined milestones for first patients dosed in HS and AD trials Topline data from two ongoing trials expected 1H 2025 Kymera and Sanofi evaluating opportunities to expand indications beyond HS and AD ● KT-474: Oral Agent with Potential to Achieve Broad, Well-Tolerated Anti-Inflammatory Effect in Multiple Diseases ● KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 19

View entire presentation